IRIDEX (NASDAQ:IRIX) Getting Somewhat Positive News Coverage, Report Shows

News articles about IRIDEX (NASDAQ:IRIX) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. IRIDEX earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 44.7986739982952 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of IRIDEX (IRIX) traded up $0.19 on Friday, hitting $7.23. The stock had a trading volume of 22,729 shares, compared to its average volume of 20,094. IRIDEX has a 12-month low of $6.67 and a 12-month high of $16.37.

A number of analysts have recently issued reports on IRIX shares. Roth Capital reiterated a “buy” rating and set a $13.00 price target on shares of IRIDEX in a research report on Friday, November 3rd. Zacks Investment Research upgraded IRIDEX from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th.

In other IRIDEX news, CEO William M. Moore purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was purchased at an average price of $7.84 per share, for a total transaction of $39,200.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.01% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “IRIDEX (NASDAQ:IRIX) Getting Somewhat Positive News Coverage, Report Shows” was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://weekherald.com/2018/02/18/iridex-irix-receiving-somewhat-favorable-press-coverage-study-shows.html.

About IRIDEX

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).

Insider Buying and Selling by Quarter for IRIDEX (NASDAQ:IRIX)

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply